Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Simple Lab Tests to Better Stratify Low Flow and Low Gradient AS Patients

Combining B-type natriuretic peptide (BNP) and high-sensitive cardiac troponin T measures undeniably helps to better stratify severe aortic stenosis patients with low flow and low gradient.  Many patients in these conditions clearly benefit from a transcatheter aortic valve replacement (TAVR) procedure, and for others it is simply useless, and given its high cost, better stratification could be of great use.  

Análisis de laboratorio sencillos para estratificar mejor el bajo flujo y bajo gradienteWe did know high BNP is associated with increased mortality in severe aortic stenosis patients (especially those with low flow and low gradient) but we ignored the incremental prognosis value of high-sensitive troponin level in these patients.

 

The study included 98 patients (74±10 years; 75% men) with low flow and low gradient aortic stenosis (ejection fraction <50% and/or stroke volume index  <35 ml/m², mean gradient <40 mmHg, indexed aortic valve area <0.6 cm²/m²), prospectively enrolled in the TOPAS trial (Truly or Pseudo-Severe Aortic Stenosis).


Read also: Direct Stenting vs. Conventional Angioplasty and Their Interaction with Thrombus Aspiration.


Patients were divided in three groups according to these levels: group 1, BNP <550 pg/ml and troponin <15 ng/ml; group 2, BNP ≥550 pg/ml or troponin ≥15 ng/ml; and group 3, with elevated levels (BNP ≥550 pg/ml and troponin ≥15 ng/ml).

 

Primary end point was all cause mortality.

 

27% of patients were found in group A, 40% in group B and 33% in group C. Two- year mortality rate was significantly higher in group C (41 ± 9%) compared against group B (23 ± 7%) and group A (5 ± 4%), (p<0.002 for all combinations).


Read also: An Effort Worth Your While: Rechanneling vs. Optimal Medical Treatment in Total Occlusions.


Group B did not show significant differences in mortality, regardless the higher level was BNP or troponin.

 

After adjusting for age, type of treatment (valve replacement or conservative treatment) associated coronary disease or ejection fraction, group C combined markers continued to be independent predictors of mortality (more than 4 times higher; p=0.023). Group B showed higher mortality compared to group A, though not significantly higher.

 

Conclusion

This study shows the use of combining BNP and troponin levels to clearly stratify these patients that, not long ago, were considered similar. High levels of these markers in the context of severe aortic stenosis with low flow and low gradient could determine the futility of aortic valve replacement.

 

Original title: B-Type Natriuretic Peptide and High-Sensitivity Cardiac Troponin for Risk Stratification in Low-Flow, Low-Gradient Aortic Stenosis. A Substudy of the TOPAS Study.

Reference: Abdellaziz Dahou et al. J Am Coll Cardiol Img 2018, Article in press.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

SCAI 2026 | Can an atrial fixation device prevent complications of transcatheter mitral valve replacement? Analysis of the AltaValve system

Transcatheter mitral valve replacement (TMVR) represents one of the most complex areas within structural interventions. Unlike TAVI, where valvular anatomy typically provides more predictable...

Beyond TAVI: Cardiac Rehabilitation as a Determinant of Clinical Outcomes

Aortic stenosis is an increasingly prevalent condition associated with population aging, with a prevalence of approximately 3.4% in individuals over 75 years of age...

Comparative outcomes between transaxillary approach and thoracotomy-based approaches in TAVI with alternative access

TAVI has become the standard treatment for high-risk aortic stenosis. When transfemoral access is not feasible (approximately 10–15%), alternative approaches are used: transaxillary (subclavian...

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

SCAI 2026 | Deep vein arterialization as an alternative in patients with critical limb ischemia without conventional options

Critical limb ischemia (CLI) represents one of the most advanced stages of peripheral arterial disease (PAD). In a significant proportion of patients, distal anatomy,...

SCAI 2026 | Can an atrial fixation device prevent complications of transcatheter mitral valve replacement? Analysis of the AltaValve system

Transcatheter mitral valve replacement (TMVR) represents one of the most complex areas within structural interventions. Unlike TAVI, where valvular anatomy typically provides more predictable...

SCAI 2026 | SELUTION DeNovo subanalysis: Use of sirolimus-eluting balloon in acute coronary syndrome

Percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation remains the predominant strategy in the setting of acute coronary syndrome (ACS). However, in recent...